Thursday, September 26, 2024 12:57:55 AM
EXPECTING LOWER
Recent CLDX News
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 04/06/2026 02:53:52 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/02/2026 09:14:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:08:18 PM
- Celldex Announces Pricing of $300 Million Public Offering of Common Stock • GlobeNewswire Inc. • 04/02/2026 01:48:19 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/01/2026 08:07:34 PM
- Celldex Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 04/01/2026 08:01:00 PM
- Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 • GlobeNewswire Inc. • 03/27/2026 02:30:00 PM
- Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease • GlobeNewswire Inc. • 03/01/2026 02:45:00 PM
- Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI • GlobeNewswire Inc. • 02/27/2026 07:45:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/25/2026 09:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 09:01:27 PM
- Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/25/2026 09:01:00 PM
- Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria • GlobeNewswire Inc. • 02/25/2026 12:01:00 PM
- Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile • GlobeNewswire Inc. • 02/23/2026 01:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/10/2026 04:21:52 PM
- Celldex to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/09/2026 01:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/17/2025 09:06:34 PM
- Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism • GlobeNewswire Inc. • 12/09/2025 01:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 09:20:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/04/2025 09:04:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2025 09:17:07 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/15/2025 12:58:46 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 10:08:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/13/2025 09:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2025 09:12:27 PM
